Recommendation of the President – Proglicem (diazoxide)
On 16 December 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 144/2024 on the appraisal of authorizing the reimbursement of the drug Proglicem (diazoxide) for the indications: insulinoma, hyperinsulinomic hypoglycemia, congenital hyperinsulinism, hypoglycemia-hyperammonemia syndrome, MEN2 syndrome, hypoglycemia unspecified, other hypoglycemias